Encore Medical, INC S-1 registration statements

Encore Medical, Inc. files S-1/A for its initial public offering, aiming to raise capital for clinical trials and market expansion.

Encore Medical, Inc. has filed an S-1/A amendment detailing its initial public offering plans and a new exclusive license for AI technology.

Encore Medical, Inc. has filed an S-1/A amendment detailing its initial public offering, aiming to raise approximately $15 million by selling 3 million shares of common stock at an expected price of $5.00 per share.

Encore Medical, Inc. has filed an S-1/A amendment to its registration statement, primarily to include Exhibit 4.3, the Form of Investor's Warrant, and an updated Filing Fee Table.

Encore Medical, a structural heart device company, is launching an IPO to raise approximately $12.7 million to finance U.S. clinical trials for its PFO septal occlusion device for stroke and migraine indications, aiming for a NYSE American listing.

Encore Medical, a structural heart device company, is launching an IPO to raise $12.96 million for critical US clinical trials for stroke and migraine indications, despite a history of net losses and going concern doubts.

Encore Medical, a structural heart device company, filed an S-1 registration statement for an initial public offering to finance its crucial U.S. clinical trials for PFO closure devices targeting stroke and migraine prevention.